organization · Reporting owner

Biotest AG

Disclosed activity across 1 company

Tapewire entity: 166607
SEC CIK: 0001709152

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ADMA BIOLOGICS, INC.ADMA · Entity 4477	10% owner	May 14, 2018	May 16, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date May 14, 2018 · Filed May 16, 2018

Jointly reported with Biotest Pharmaceuticals Corp

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Voting Common StockSEC Table I · non-derivative	IndirectBy Biotest Pharmaceuticals Corporation	0	Reported balance After 2018-05-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-05-14 · Sale · Disposed 8,591,160 · Balance 0 F1: On May 14, 2018, pursuant to a Share Transfer, Amendment and Release Agreement, by and among, among other parties, the issuer, Biotest Pharmaceuticals Corporation ("BPC") and Biotest AG, BPC transferred to the issuer, for no cash consideration, 8,591,160 shares of the issuer's non-voting common stock previously issued to BPC in June 2017 and representing 100% of the issuer's then-issued and outstanding non-voting common stock. F2: The shares were owned directly by BPC, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG.
Common StockSEC Table I · non-derivative	IndirectBy Biotest Pharmaceuticals Corporation	10,109,534	Reported balance Holding disclosure · report date 2018-05-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 10,109,534 F3: The shares are owned directly by BPC, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG.

Filing footnotes · ownership attribution and instrument terms

F1: On May 14, 2018, pursuant to a Share Transfer, Amendment and Release Agreement, by and among, among other parties, the issuer, Biotest Pharmaceuticals Corporation ("BPC") and Biotest AG, BPC transferred to the issuer, for no cash consideration, 8,591,160 shares of the issuer's non-voting common stock previously issued to BPC in June 2017 and representing 100% of the issuer's then-issued and outstanding non-voting common stock.

F2: The shares were owned directly by BPC, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG.

F3: The shares are owned directly by BPC, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 14, 2018 Filed May 16, 2018 21:00 UTC	ADMA BIOLOGICS, INC. ADMA · Entity 4477	SaleNon-Voting Common Stock	8,591,160	$0.00	$0.00	Disclosure SEC source: 0001193805-18-000697 · e618019_4-biotest.xml · nonDerivative · entry 1 Biotest AG · CIK 0001709152 · 10% owner Biotest Pharmaceuticals Corp · CIK 0001708960 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 0 F1 · shares: On May 14, 2018, pursuant to a Share Transfer, Amendment and Release Agreement, by and among, among other parties, the issuer, Biotest Pharmaceuticals Corporation ("BPC") and Biotest AG, BPC transferred to the issuer, for no cash consideration, 8,591,160 shares of the issuer's non-voting common stock previously issued to BPC in June 2017 and representing 100% of the issuer's then-issued and outstanding non-voting common stock. F2 · ownership.nature: The shares were owned directly by BPC, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG. Read SEC document
November 09, 2017 Filed Nov 13, 2017 18:54 UTC	ADMA BIOLOGICS, INC. ADMA · Entity 4477	PurchaseCommon Stock	5,813,954	$2.15	$12,500,001.10	Disclosure SEC source: 0001193805-17-003457 · e617475_4-biotest.xml · nonDerivative · entry 1 Biotest AG · CIK 0001709152 · Director · 10% owner Biotest Pharmaceuticals Corp · CIK 0001708960 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 10,109,534 F1 · shares: Represents a purchase from the underwriters in the issuer's public offering. F2 · ownership.nature: The shares are owned directly by Biotest Pharmaceuticals Corporation, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG. Biotest AG is a director and a ten percent owner of the issuer. Read SEC document
November 09, 2017 Filed Nov 17, 2017 02:32 UTC Amendment	ADMA BIOLOGICS, INC. ADMA · Entity 4477	PurchaseCommon Stock	5,813,954	$2.15	$12,500,001.10	Disclosure SEC source: 0001193805-17-003506 · e617500_4a-biotest.xml · nonDerivative · entry 1 Biotest AG · CIK 0001709152 · Director · 10% owner Biotest Pharmaceuticals Corp · CIK 0001708960 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Biotest Pharmaceuticals Corporation Disclosed balance after: 10,109,534 F1 · shares: Represents a purchase from the underwriters in the issuer's public offering. F2 · ownership.nature: The shares are owned directly by Biotest Pharmaceuticals Corporation, a ten percent owner of the issuer and a wholly owned subsidiary of Biotest AG, and indirectly by Biotest AG. Biotest AG is a director and a ten percent owner of the issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.